Risk factors for adverse cardiovascular events in liver transplantation

ISRCTN ISRCTN16660149
DOI https://doi.org/10.1186/ISRCTN16660149
Submission date
04/02/2025
Registration date
06/02/2025
Last edited
06/02/2025
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Circulatory System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Background and study aims
Liver cirrhosis is a terminal and irreversible stage of chronic hepatic disease. The etiology is various and includes alcohol, infections, carcinoma, medicaments and toxins, immune disease, cholestasis, metabolic causes, sarcoidosis etc. Therapy in end-stage liver disease is liver transplantation. A cadaveric orthotopic transplantation liver graft is a liver transplant where the donor organ (the graft) is taken from a deceased person (cadaver) and placed in the recipient's body in the same anatomical position as their native liver, replacing it completely. The donor and recipient's factors influence the transplantation procedure and its outcome, affecting post-transplant morbidity and mortality. Liver transplantation poses a high risk for cardiovascular complications and cardiac death. It can reverse certain pathologic states induced by hepatic disease but it can also lead to acute decompensation and cardiac death. Current studies show different incidences of cardiovascular adverse events during and after liver transplantation, without connecting donor-recipient traits to these events. This study aims to find the incidence of adverse cardiovascular events during orthotopic liver transplantation and during early posttransplant time and to establish which factors, donor and recipient, contribute to these adverse events. Furthermore, the study will create a simple grading scale that allows us to predict the incidence of severe cardiovascular adverse events in this vulnerable group of patients.

Who can participate?
All patients aged 18 years old and over who were admitted to University Hospital Merkur, Zagreb, Croatia for liver transplants between 2013 and 2015

What does the study involve?
The medical records of patients who are admitted for liver transplantation are reviewed, including their charts during and after surgery. Information about the donors is obtained from Eurotransplant donor reports. Scoring systems will be used to model the study outcomes.

What are the possible benefits and risks of participating?
The overall benefit of the study is for further patients who will be undergoing liver transplantation in future. Since this is an observational, non-intervention retrospective chart review study, there is no risk for participants.

Where is the study run from?
University Hospital Merkur (Klinička bolnica Merkur)

When is the study starting and how long is it expected to run for?
January 2013 to July 2016

Who is funding the study?
Investigator initiated and funded

Who is the main contact?
Nataša Višković Filipčić, MD., natasa.viskovic-filipcic@agram-bolnica.hr, natashav7@gmail.com

Contact information

Mrs Nataša Višković Filipčić
Public, Scientific, Principal Investigator

Školska 25
Velika Mlaka
10408
Croatia

ORCiD logoORCID ID 0009-0009-5804-3912
Phone +385 0913355998
Email natasa.viskovic-filipcic@agram-bolnica.hr
Mrs Nataša Višković Filipčić
Public, Scientific, Principal Investigator

Školska 25
Velika Mlaka
10408
Croatia

Phone +385 0913355998
Email natashav7@gmail.com

Study information

Study designSingle-center 3-year observational study
Primary study designObservational
Secondary study designCohort study
Study setting(s)Hospital, Medical and other records
Study typePrevention
Participant information sheet No participant information sheet available
Scientific titleRisk factors associated with adverse cardiovascular events during orthotopic liver transplantation and during early posttransplant time
Study acronymACV-OLT
Study objectivesThe incidence of adverse cardiovascular events during orthotopic liver transplantation and early posttransplant time is less than 5%.
Ethics approval(s)

Approved 01/12/2014, Ethics Committee of University Hospital Merkur (Zajčeva 19, Zagreb, 10000, Croatia; +385 1 2353 801; eticko.povjerenstvo@kb-merkur.hr), ref: 0311-13652

Health condition(s) or problem(s) studiedAdverse cardiovascular events in patients eligible for liver transplantation during the procedure itself and early posttransplant time
InterventionMedical records of patients admitted for liver transplantation and their intraoperative and postoperative charts are examined. Donor data are acquired from Eurotransplant donor reports. Any subsequent scores are calculated according to official scoring systems ( MELD, DRI).
Intervention typeProcedure/Surgery
Primary outcome measureTo establish the incidence of adverse cardiovascular events in a group of patients with liver transplantation during the transplant procedure and early posttransplant time (30 days) measured using data collected from patient medical records at one time point
Secondary outcome measuresThe following secondary outcome measures are evaluated measured using data collected from patient medical records at one time point:
1. Donor and recipient characteristics in a subgroup of patients with severe adverse cardiovascular events
2. The risk of adverse cardiovascular complications in the subgroup of patients with severe adverse cardiovascular events defined using a simple grading scale
3. To create a simple scale based on donor and recipient characteristics, used for risk assessment
Overall study start date01/01/2013
Completion date10/07/2016

Eligibility

Participant type(s)Patient
Age groupMixed
Lower age limit18 Years
Upper age limit100 Years
SexBoth
Target number of participants205
Total final enrolment291
Key inclusion criteria1. Patients admitted and undergoing liver transplantation in UH Merkur, Zagreb, Croatia
2. 18 years of age and older
Key exclusion criteria1. Age less than 18 years
2. Liver re-transplantation
3. Acute liver failure
4. Living donor liver transplantation
5. Multiorgan transplantation
Date of first enrolment10/08/2015
Date of final enrolment10/07/2016

Locations

Countries of recruitment

  • Croatia

Study participating centre

University Hospital Merkur
Zajčeva ulica 19
Zagreb
10000
Croatia

Sponsor information

Klinička bolnica Merkur
Hospital/treatment centre

Zajčeva 19
Zagreb
10000
Croatia

Phone +385 1 2431 390
Email ravnateljstvo@kb-merkur.hr
Website https://www.kb-merkur.hr/
ROR logo "ROR" https://ror.org/01b6d9h22

Funders

Funder type

Other

Investigator initiated and funded

No information available

Results and Publications

Intention to publish date30/06/2025
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot expected to be made available
Publication and dissemination planPlanned publication in a peer-reviewed journal.
IPD sharing planThe dataset generated and/or analysed during the current study are not expected to be made available due to transplant laws and regulations

Editorial Notes

05/02/2025: Study's existence confirmed by the Ethics Committee of University Hospital Merkur.